CYSTEAMINE FOR THE TREATMENT, MITIGATION AND PREVENTION OF CORONAVIRAL, E.G., SARS-CoV-2, INFECTIONS
AssigneeThe Regents of the University of Michigan
InventorsJess Thoene, Robert Gavin
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.
Claims20
A method of preventing, mitigating, or treating infection with a coronavirus or a disease associated with a coronavirus infection in a subject, the method comprising:
- administering a formulation comprising an effective dose of an active agent selected from cysteamine, cystamine and phosphocysteamine to the subject.
A method of preventing, mitigating, or treating infection with a coronavirus in a subject, the method comprising:
- nasally administering a formulation comprising an effective dose of an active agent selected from cysteamine, cystamine and phosphocysteamine to the subject, wherein mitigating infection with the coronavirus includes reducing viral infectivity or replication in cells exposed to the active agent relative to cells not exposed to the active agent.
Dependencies are inferred from the claim text.